Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Indian stock markets shed initial gains
Mon, 12 Mar 01:30 pm

Indian stock markets indices have shed initial gains during the last two hours of trade. consumer durables and capital goods stocks witnessed maximum buying interest while IT stocks witnessed maximum selling pressure.

The BSE-Sensex is up by 77 points, while the NSE-Nifty is up by 26 points. BSE Mid cap index and the BSE Small cap index are up by 0.85% and 0.65% respectively. The rupee is trading at 49.94 to the US dollar.

As per a leading financial daily, Index of industrial Production (IIP) accelerated by 6.8% YoY in January 2012 from 1.8% YoY increase in the preceding month. The pick-up in momentum has come on the back of an 8.5% rise in the output of the manufacturing sector that constitutes three fourths of the index. Even electricity recorded a robust growth of 3.2% but mining output declined by 2.7% in January. As per Use-based classification, basis goods output grew by 1.6% whereas capital good and intermediate goods saw production declining by 1.5% and 3.2%, respectively during the month. Consumer goods output recorded a steep jump of 20.2% on a 42% jump in consumer non-durables. On a cumulative basis , IIP expanded by 4% during April-January 2012 .

Pharma stocks have been trading mixed with Wockhardt and Torrent Pharma leading the gainers and Cipla and Glenmark Pharma trading the weakest. As per a leading financial daily, Biocon is planning to enter US markets from Financial Year 2013 by selling its anti-cholesterol drug- atorvastatin. The market for atorvastatin has recently opened up in US for generic companies. In doing so, the company is following footsteps of Watson and Ranbaxy, that have already launched their products in the US markets and are currently under six months exclusivity phase. The company has seen considerable growth in branded atorvastatin (Statix) and sales of active pharmaceutical ingredients (API). Besides, Biocon is also planning to tap the European market, where it has been selling atorvastatin with its partners. The company has a significant presence in emerging and unregulated markets with Statix. The stock was trading in the red.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian stock markets shed initial gains". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.